Document Detail


Multiple mechanisms of ligand interaction with the human organic cation transporter, OCT2.
MedLine Citation:
PMID:  23034939     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OCT2 is the entry step for organic cation (OC) secretion by renal proximal tubules. Although many drugs inhibit OCT2 activity, neither the mechanistic basis of their inhibition nor their transport status is generally known. Using representatives of several structural classes of OCT2-inhibitory ligands described recently (Kido Y, Matsson P, Giacomini KM. J Med Chem 54: 4548-4558, 2011), we determined the kinetic basis of their inhibition of 1-methyl-4-phenylpyridinium (MPP) transport into Chinese hamster ovary cells that stably expressed hOCT2. The "cluster II" inhibitors (which contain known OCT2 substrates) metformin and cimetidine interacted competitively with MPP. However, other cluster II compounds, including tetraethylammonium (TEA), diphenidol and phenyltoloxamine, were mixed-type inhibitors of MPP transport (i.e., decreasing J(max) and increasing K(t)). A cluster III (neutral steroid) representative, adrenosterone, and a cluster I (large, flexible cation) representative, carvedilol, displayed noncompetitive inhibitory profiles. Competitive counterflow (CCF) was used to determine whether the inhibitory ligands served as substrates of hOCT2. Carvedilol (cluster I) and adrenosterone (cluster III) did not support CCF, consistent with the prediction that members of these structural classes are likely to be nontransported inhibitors of OCT2. The cluster II representatives MPP, metformin, cimetidine, and TEA all supported CCF, consistent with independent assessments of their OCT2-mediated transport. However, the other cluster II representatives, diphenidol and phenyltoloxamine, failed to support CCF, suggesting that neither compound is transported by OCT2. An independent assessment of diphenidol transport (using liquid chromatography with tandem mass spectroscopy) confirmed this observation. The results underscore the caution required for development of predictive models of ligand interaction with multidrug transporters.
Authors:
Jaclyn N Harper; Stephen H Wright
Related Documents :
24565909 - Discovery of 3-(4-hydroxybenzyl)-1-(thiophen-2-yl)chromeno[2,3-c]pyrrol-9(2h)-one as a ...
23792159 - Structural evidence for native state stabilization of a conformationally labile amyloid...
23291469 - Detection of a quaternary organization into dimer of trimers of corynebacterium ammonia...
24436249 - Structural basis for the inhibition of akr1b10 by caffeic acid phenethyl ester (cape).
23667909 - Mast cells limit extracellular levels of il-13 via a serglycin proteoglycan-serine prot...
2400399 - Effect of n-methylation on the modulation by synthetic peptides of the activity of the ...
7988699 - A point mutation within the atp-binding site inactivates both catalytic functions of th...
19325759 - Effect of locked-nucleic acid on a biologically active g-quadruplex. a structure-activi...
24064219 - Biochemical analysis and structure determination of bacterial acetyltransferases respon...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2012-10-03
Journal Detail:
Title:  American journal of physiology. Renal physiology     Volume:  304     ISSN:  1522-1466     ISO Abbreviation:  Am. J. Physiol. Renal Physiol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-02     Completed Date:  2013-04-03     Revised Date:  2014-04-02    
Medline Journal Info:
Nlm Unique ID:  100901990     Medline TA:  Am J Physiol Renal Physiol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  F56-67     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
1-Methyl-4-phenylpyridinium / metabolism*
Androstenes / pharmacology
Animals
Benzhydryl Compounds / metabolism
CHO Cells
Carbazoles / pharmacology
Cimetidine / metabolism
Cricetinae
Cricetulus
Humans
Inhibitory Concentration 50
Kinetics
Ligands
Metformin / metabolism
Organic Cation Transport Proteins / antagonists & inhibitors,  metabolism*
Piperidines / metabolism
Propanolamines / pharmacology
Tetraethylammonium / metabolism
Grant Support
ID/Acronym/Agency:
5P30E006694//PHS HHS; 5R01DK58251/DK/NIDDK NIH HHS; 5T32HL07249/HL/NHLBI NIH HHS; P30 ES006694/ES/NIEHS NIH HHS; R01 DK058251/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
0/Androstenes; 0/Benzhydryl Compounds; 0/Carbazoles; 0/Ligands; 0/Organic Cation Transport Proteins; 0/Piperidines; 0/Propanolamines; 0/SLC22A2 protein, human; 0K47UL67F2/carvedilol; 66-40-0/Tetraethylammonium; 80061L1WGD/Cimetidine; 9100L32L2N/Metformin; AE4E9102GY/adrenosterone; K65LB6598J/phenyltoloxamine; NQO8R319LY/diphenidol; R865A5OY8J/1-Methyl-4-phenylpyridinium
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Zona occludens-2 protects against podocyte dysfunction induced by ADR in mice.
Next Document:  A regulated NH2-terminal Sgk1 variant with enhanced function is expressed in the collecting duct.